
The Promise of AI and Cardiovascular Diseases for PCPs
Physician outlooks on artificial intelligence (AI) vary, but most will tell you they're open to using it. AI as a tool to improve the administrative side of medicine is widely embraced, as is AI in medical imaging. But what is its role in helping detect cardiovascular diseases in the primary care setting? As with all areas of AI in medicine, that's an evolving picture.
In an official statement, the American Heart Association (AHA) said it supports the creation of tools and services that would 'further the science and practice of precision medicine by enabling more precise approaches to cardiovascular and stroke research, prevention and care of individuals and populations.'
Nevertheless, the AHA continued, 'several challenges exist, and few artificial intelligence tools have been shown to improve cardiovascular and stroke care sufficiently to be widely adopted.'
Still, AI isn't going anywhere, and the push for its use in cardiovascular disease prediction and treatment will only increase.
'AI is everywhere in the healthcare system,' said Hector Garcia-Garcia, MD, an interventional cardiologist with MedStar, based in Washington, D.C. 'AI tools are involved with labs, imaging, values, and more, and it's well integrated into electronic medical records today.'
Hector Garcia-Garcia, MD
The role of primary care physicians (PCPs) continues to be critical in heart disease detection. As frontline healthcare workers, PCPs are generally the first to note something amiss when it comes to patient cardiovascular health.
'PCPs are crucial to identifying cardiovascular health risks,' said Anthony Mercando, MD, a cardiologist at White Plains Hospital Physician Associates in New York City. 'They take family histories, do physical exams, and get blood panel results, all of which may show cause for investigating heart health.'
While all these traditional tools have long led PCPs to refer patients to their cardiologist peers, today AI is increasingly involved in screening. And that may be a boon, as a high percentage of heart diseases go undiagnosed.
The AI-Enhanced Tools
If there's a traditional workhorse in the world of heart disease, it's the stethoscope. And now, AI has joined the show, promising to enhance the tool's ability to pick up subtle changes. Preliminary studies have demonstrated that AI-enhanced stethoscopes may lead to higher discovery and earlier diagnosis of cardiac murmurs associated with valvular heart disease, which affects 1 in 10 adults older than 65 years.
The new stethoscopes work by making a 30- to 60-second recording of the patient's heart and lung sounds. Doctors also hear the sounds with greater clarity, thanks to amplification and noise cancellation. From here, AI steps in, instantly analyzing the sounds and ECG data to deliver a full picture of cardiac health — sometimes in as quickly as 15 seconds. The stethoscope represents a big step forward in early diagnosis, according to a Lancet-published study.
Mercando is a fan of the new tool.
'We're doing a pilot here to screen patients who are not yet symptomatic or have abnormal test results,' he said. 'It's an exciting tool to pick up disease earlier in the process, and it's a tool that any healthcare practitioner can use.'
The stethoscope is one example of how AI can enhance diagnosis of heart diseases, and represents a low-cost, frontline tool that PCPs can add to their practices. Other tools are less obvious, at least to the patient.
One of these is imaging, a key player in heart disease diagnosis. CT scans of the heart have long been stalwarts in recognizing heart disease. For a relatively low cost, a scan can reveal three-dimensional images of a heart and its surrounding structures. Cardiac CT may involve contrast dye to reveal the moving heart and blood vessels.
In the AI-enhanced version, CT can produce faster analysis of the images it takes. 'The AI is digging into hundreds of data points and is key in making the results faster,' said Garcia-Garcia. 'The results are always supervised by a cardiologist, but the AI is giving us the ability to identify red flags faster and earlier.'
Anthony Mercando, MD
Still, as with other uses of AI in medicine, it's important to recognize the clinical correctness of the results may not be perfect— thus the continued need for human intervention. According to the AHA's statement on CT imaging using AI, the applications are now 'capable of automating the computing of coronary artery calcium score' from low-dose CT or even from nuclear imaging studies.
'There's no AI tool in the United States that isn't supervised by the doctor, so the final word lies with the doctor,' said Garcia-Garcia. 'Therefore, there is no real downside.'
At Mercando's community hospital, the newly created position of AI coordinator is looking into relevant applications for AI. One of those is a solution that looks at every chest CT and creates a calcium score. 'When you have a tool that can predict risk and allow specialists to treat patients earlier, you are saving lives,' said Mercando.
Going Forward
As a PCP, you may or may not be tuned into how AI is helping your cardiac/potential cardiac patients. But as the technology becomes more widespread and the public becomes more aware, patients may bring it into conversation.
'A classic example is how AI is now reading mammograms, identifying differences from 1 year to the next,' said Mercando. 'Patients are aware of this and now asking for it. The same may carry over to heart disease — patients are supportive of the technology.'
AI in cardiac care isn't limited to stethoscopes and CT — its tentacles are beginning to reach into structural interventions like measuring stenosis, and by automatically detecting intracranial hemorrhage in stroke diagnosis.
In its statement, the AHA warns against AI limitations specific to imaging. The group points to sourcing, curating, and sharing appropriate data as one sticking point, along with questions surrounding the appropriate reporting of results using accepted statistical measures. The AHA suggests that deep learning algorithms may be enhanced by using a new medical imaging data readiness scale for improved outcomes.
As with all medical uses of AI, the AHA also cautions against bias leading to health inequities. The organization encourages the development of AI learning models that involve underrepresented races in cardiac care. The tool is far from perfected yet, but its potential will continue to intrigue doctors of all stripes, including cardiologists.
Moving forward, the fact that AI will play an increasingly larger role in cardiovascular screening isn't up for debate. What is debatable is the point when will the tool be useful to improving patient outcomes at scale. In the AHA's opinion, the answer lies in the need to mitigate bias and ensure education and access to AI technologies. Only then, said the organization, can AI realize its full potential.
From his perspective, Garcia-Garcia views AI's role in cardiovascular care as a game changer. 'AI can change how a patient is treated,' he said. 'Early detection gets patients to specialists sooner, and that saves lives.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
From AI to aerospace: Europe's most innovative companies shaping tomorrow
What does innovation look like in 2025? From AI to blockbuster weight-loss drugs, Europe's forward-thinking companies punch above their weight. For the first time, Fortune analyzed the top companies across the continent in partnership with Statista to find the standouts that are driving progress with success. Patent data was provided by LexisNexis Intellectual Property Solutions. The list features 300 companies across 21 countries and 16 industries, and a total of 168 of the companies are on the Fortune 500 Europe. Companies on the list have brought in just under $8 trillion in annual revenue. The U.K. has more companies on our list than any other country, followed by Germany and Switzerland. The top sectors are finance, followed by retail and industrials. Companies on the list have brought in just under $8 trillion in annual revenue. The list features 300 companies across 21 countries and 16 industries, and a total of 168 of the companies are on the Fortune 500 Europe. Companies on the list have brought in just under $8 trillion in annual revenue. The U.K. has more companies on our list than any other country, followed by Germany and Switzerland. The top sectors are finance, followed by retail and industrials. L'Oréal was ranked at the top of the list in 2025. 'We are immensely proud to be recognized by Fortune as Europe's most innovative company,' Nicolas Hieronimus, Chief Executive Officer of L'Oréal told Fortune. 'This prestigious recognition reinforces our conviction that innovation, fueled by science, technology, and creativity, is the best way to succeed on the world stage, but is also a testament to the incredible talent and dedication of our teams around the globe.' We've highlighted some of the standout companies from this year's list driving innovation across Europe. Household products Noted for: Product innovation Employees: 50,000–99,999Fortune 500 Europe rank: 91France L'Oréal invests more than €1 billion annually in research and innovation and boasts a team of over 4,000 researchers. This, in turn, helps the French company formulate new ingredients and develop new products. Earlier this year, L'Oréal launched a device called Cell BioPrint that will give people a detailed assessment of their skin and the products best suited for it. 'This prestigious recognition reinforces our conviction that innovation, fueled by science, technology, and creativity, is the best way to succeed on the world stage…' Nicolas Hieronimus, CEO, L'Oréal Household products Product innovationEmployees: >100,000F500 Europe rank: 49U.K. Unilever's innovations take different shapes and forms—from fast-action laundry liquid to paper-cup instant noodles. The London-based company has 20,000 patents and a team of 5,000 experts who design new products, aided by nearly €1 billion in annual investments. Unilever has also expanded its AI use to help customers find the best products and discover new ones backed by scientific data. Health careProduct innovationEmployees: 50,000–99,999F500 Europe rank: 210Netherlands Founded in 1891, Royal Philips is known for pioneering innovations in lighting, health care, and consumer electronics. Key breakthroughs include the first compact audio cassette, electric razors, and mercury-free light bulbs. Today, Philips leads in sustainable, health–focused technology, improving billions of lives globally. Health careInnovation cultureEmployees: 50,000–99,999F500 Europe rank: 104U.K. GSK's innovations were reflected in its bottom line in 2024. With the help of its Silicon Valley veteran technology chief, Shobie Ramakrishnan, GSK is also using AI to speed drug discovery and streamline its supply chains. Health careInnovation cultureEmployees: 50,000–99,999F500 Europe rank: 116Denmark Novo Nordisk is wasting little time in developing new obesity treatments that, until recently, made it Europe's most valuable company. In May, the FDA accepted Novo's application to sell an oral version of Wegovy; an approval decision is expected in Q4. Novo Nordisk's recent trials for CagriSema, a new, more effective weight-loss medication, could increase its appeal beyond the millions already using its drugs. Health careProcess innovationEmployees: 50,000–99,999F500 Europe rank: 125Ireland In 2024, Medtronic invested more than $2.7 billion in R&D and operated over 81 manufacturing sites. AI is used to customize patient care, ranging from personalized brain therapy to data-driven diabetes care. The use of robotic-assisted surgery (RAS) also helps enhance precision and control. RetailingProduct innovationEmployees: >100,000F500 Europe rank: 144France Whether with Ray-Ban Meta glasses or its latest audio-enhancing eyewear, EssilorLuxottica is always pioneering new technology. Nearly 1,000 researchers across 50 R&D sites supported by up to €350 million in investment help the Franco-Italian company stay ahead of trends. The company is also vertically integrated, allowing for better quality control globally. Click here to view the full list. This story was originally featured on
Yahoo
24 minutes ago
- Yahoo
Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025
BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center. The company will exhibit at Booth #1851, presenting its differentiated pipeline, including the flagship Phase 1 immunocytokine FP008, a portfolio of promising early-stage candidates for oncology and autoimmune diseases, and its suite of proprietary technology platforms, while actively seeking global partnerships. FP008, Fapon Biopharma's lead asset, is a first-in-class immunocytokine currently in Phase 1 clinical trials, designed to address significant unmet needs in solid tumor patient refractory to anti-PD-1 therapy. The company will also feature promising preclinical candidates targeting oncology (FP010, FP011, FPE021) and autoimmune diseases (FPE022, FPE024), highlighting its expanding research capabilities. Fapon Biopharma will feature its proprietary and innovative technology platforms, engineered to overcome complex drug development challenges: Bi/Tri-TCE Platform: Human-monkey cross-reactive TCR/CD3 nanobody, enabling the design of potent multi-specific antibodies for targeted cancer immunotherapy. FILTEN™ (IL-10M Fusion Protein Platform): Overcoming IL-10 limitations for broad applications in cancer and autoimmune diseases PROTiNb™ (Proteolysis Targeting Intra-Nanobody): A pioneering platform targeting previously "undruggable" intracellular targets, demonstrating a strong competitive edge. FIND™ Mammalian Cell Display Platform: Accelerating antibody discovery by combining mammalian cell expression with high-throughput screening. "We are excited to connect with the global biopharma community at BIO 2025," said Vincent Huo, President of Fapon Biopharma. "We look forward to demonstrating the exciting progress of our internal pipeline and how our technology platforms can empower external partners to bring transformative therapy to patients faster." Engagement Opportunities:Exhibition Booth: #1851Company Presentation: Time: 11:30 a.m., Tuesday, June 17, 2025Location: Room 153A, Boston Convention & Exhibition Center To schedule a meeting in advance or during the conference, please contact our BD representatives, Max Wang ( and Liyan Gao ( or visit us at Booth #1851. Meetings can also be requested via the BIO partnering system. About Fapon Biopharma ( Fapon Biopharma specializes in discovering and developing biologics for treating cancers, autoimmune diseases and other diseases where there are unmet medical needs. Leveraging cutting-edge technologies, we have built advanced drug discovery platforms, including an antibody discovery platform based on the globally leading mammalian cell display technology, a platform for generating IL-10M fusion proteins, and a platform for developing multispecific antibodies using Fibody and nanobodies. With a differentiated pipeline of leading drug candidates, we have established capabilities that cover the entire drug development process from drug discovery, preclinical research, Chemistry, Manufacturing and Controls (CMC) to early clinical development. Committed to innovation, we strive to deliver safer, more efficacious, affordable, and accessible biologics for everyone. View original content to download multimedia: SOURCE Fapon Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
30 minutes ago
- Yahoo
Frederick County Health Department to offer free HIV testing
The Frederick County Health Department will offer free HIV testing as part of National HIV Testing Day this month. The free testing event will take place between 10 a.m. and 6:30 p.m. on June 27 at the Walgreens on Opossumtown Pike. The Frederick County Health Department staff will be available during the event to answer questions, provide education and connect people to additional prevention and care services such as pre-exposure prophylaxis (PReP). PReP is a medication that can reduce the risk of transmission in the event of an HIV exposure. National HIV Testing Day was first observed on June 27, 1995, according to The purpose of the day is 'to encourage people to get tested for HIV, know their status, and get linked to care and treatment.' Between 2019 and 2023, 66 people in Frederick County were diagnosed with HIV, according to data from the Maryland Department of Health's Infectious Disease Prevention and Health Services Bureau. For the majority of people diagnosed in that time frame, the HIV infection had not progressed to AIDS. Outside of the June 27 event, the Frederick County Health Department offers free walk-in testing on Tuesdays and Fridays from 9 a.m. to 3 p.m. and by appointment by calling 301-600-3117. All tests are confidential. More information about HIV services in Frederick County can be found at — Ceoli Jacoby